Clinical Trial

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Study acronym: REIMAGINE
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-15; most recent amendment 2025-07-30.
Status change: Recruiting → Active, Not Recruiting 2025-07-02
Status change: Not Yet Recruiting → Recruiting 2025-02-25
Trial Details
NCT Number NCT06041386
Lead Sponsor GlaxoSmithKline
Conditions Asthma
Enrollment 336 participants
Start Date 2024-03-20
Primary Completion 2025-01-31 (estimated)
Study Completion 2028-06-14 (estimated)
Updated on ClinicalTrials.gov 2025-08-01